Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Clinical results after treatment with a patient customised mini metal implant for focal cartilage damage in the knee”, has been accepted for a podium presentation at the Swedish Orthopaedic Society’s annual congress, which will take place in Malmö, Sweden, on August 29 – September 2, 2022. The presentation will be held by Prof. Karl Eriksson from Stockholm South Hospital and The Karolinska Institute, Stockholm, Sweden.

The abstract reports on the clinical outcome for patients having undergone treatment with Episurf Medical’s personalised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee, at Stockholm South Hospital.

“The study performed at Stockholm South Hospital is the first prospective, investigator-initiated study with follow up of Episealer® patients. We highly appreciate this initiative, and we are happy that the Swedish Orthopaedic Society decided to accept this abstract for a podium presentation, which confirms the interest in the clinical results of our technology. We are looking forward to taking part of the results from this ongoing study”, says Pål Ryfors, CEO Episurf Medical.